PCSK9 Inhibitors: Heralding A New Era In Dyslipidemia Management

Journal Title: BMH Medical Journal - Year 2019, Vol 6, Issue 4

Abstract

Dyslipidemia is a well known risk factor for cardiovascular disease. Till now statins were the sheet anchor of therapy for dyslipidemia. But there are a few patients who are intolerant to statins and some who develop cardiovascular disease in spite of maximally tolerated dose of statins. Still there are some others like those with familial hypercholesterolemia who do not achieve adequate reduction of cholesterol levels with statins alone or in combination with ezetimibe. Now we have a new group of medications - proprotein convertase subtilsin-kexin type 9 (PCSK9) inhibitors, to cater to these group of patients.

Authors and Affiliations

Johnson Francis

Keywords

Related Articles

Anaesthesia for Coarctation of Aorta in Pregnancy - A challenge

Coarctation of thoracic aorta is present in approximately 5-7% of patients with congenital heart disease. Coarctation of aorta (CoA) is usually characterised by a discrete narrowing of the aorta distal to the subclavian...

Impact of Emotional Intelligence on Academic Achievement and Leadership

Emotional intelligence is the ability to perceive, appraise and control one's emotions. It is the ability to motivate oneself even in stressful situations, to control impulsive behaviour and to manage feelings in perfect...

Ebola Virus Disease

Ebola virus is named after the river in the former Zaire where a haemorrhagic fever initially identified in 1976 involved human to human transmission, as well as spread by contaminated injection equipments. Ebola virus c...

Safety in Anaesthesia

From the first reported anaesthesia mishap onwards (Hannah Greener about 170 years ago) anaesthesiologists were always concerned about the safety of their patients. Anaesthesia - related mortality is always an important...

A Case Of Local Tetanus

A 38 year old lady was admitted to the hospital for with difficulty to extend the fingers of right hand following an injury to the dorsum of right hand. Based on a clinical diagnosis of local tetanus, she was treated ac...

Download PDF file
  • EP ID EP648141
  • DOI -
  • Views 127
  • Downloads 0

How To Cite

Johnson Francis (2019). PCSK9 Inhibitors: Heralding A New Era In Dyslipidemia Management. BMH Medical Journal, 6(4), 97-99. https://europub.co.uk/articles/-A-648141